ATE406159T1 - Behandlung von hyperlipidämie - Google Patents

Behandlung von hyperlipidämie

Info

Publication number
ATE406159T1
ATE406159T1 AT02729013T AT02729013T ATE406159T1 AT E406159 T1 ATE406159 T1 AT E406159T1 AT 02729013 T AT02729013 T AT 02729013T AT 02729013 T AT02729013 T AT 02729013T AT E406159 T1 ATE406159 T1 AT E406159T1
Authority
AT
Austria
Prior art keywords
hyperlipidemia
treatment
rar
mammal
inverse agonist
Prior art date
Application number
AT02729013T
Other languages
English (en)
Inventor
Yang-Dar Yuan
Scott Thacher
Elliot Klein
Roshantha Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE406159T1 publication Critical patent/ATE406159T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polarising Elements (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
AT02729013T 2001-05-03 2002-04-26 Behandlung von hyperlipidämie ATE406159T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/848,159 US20020193403A1 (en) 2001-05-03 2001-05-03 Methods of treating hyperlipidemia

Publications (1)

Publication Number Publication Date
ATE406159T1 true ATE406159T1 (de) 2008-09-15

Family

ID=25302507

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02729013T ATE406159T1 (de) 2001-05-03 2002-04-26 Behandlung von hyperlipidämie

Country Status (7)

Country Link
US (3) US20020193403A1 (de)
EP (2) EP1392284B1 (de)
JP (1) JP2004532239A (de)
AT (1) ATE406159T1 (de)
CA (1) CA2445504A1 (de)
DE (1) DE60228567D1 (de)
WO (1) WO2002089781A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
EP1701934B1 (de) * 2003-12-26 2009-02-25 Allergan, Inc. DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
WO2005093426A2 (en) * 2004-03-26 2005-10-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara)
LT1937244T (lt) 2005-09-30 2018-11-12 Io Therapeutics, Llc Vėžio gydymas specifiniais rxr agonistais
CN101472572B (zh) * 2006-05-16 2012-10-10 Io治疗有限责任公司 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
US20140094512A1 (en) * 2012-10-02 2014-04-03 Nikolas Gunkel Method of modulating the degree of adipose tissue deposited intramuscularly
PE20160664A1 (es) 2013-06-27 2016-07-09 Pfizer Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
KR102149321B1 (ko) 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
WO2017151833A1 (en) * 2016-03-02 2017-09-08 Smith & Nephew, Inc. Soft tissue repair instruments and method
KR102549273B1 (ko) 2016-03-10 2023-06-28 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
NZ745704A (en) 2016-03-10 2019-04-26 Io Therapeutics Inc Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
EP3684348A4 (de) 2017-09-20 2021-08-18 IO Therapeutics, Inc. Behandlung von krankheiten mit estern von selektiven rxr-agonisten
EP3806839B1 (de) * 2018-06-14 2024-08-07 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Agonist des retinsäure-rezeptors beta2 mit kardioprotektiven effekten
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
WO2021127250A1 (en) * 2019-12-19 2021-06-24 Orphagen Pharmaceuticals, Inc. Rar-alpha compounds for inflammatory disease and male contraception
EP4444287A4 (de) 2021-12-07 2025-05-28 Io Therapeutics, Inc. Verwendung eines rxr-agonisten und taxanen zur behandlung von her2+-krebs
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
EP0638071B1 (de) 1992-12-28 1997-04-09 Eisai Co., Ltd. Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6218128B1 (en) 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5728846A (en) 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
US5998654A (en) * 1997-07-25 1999-12-07 Ligand Pharmaceuticals Incorporated Retinoic acid receptor antagonist compounds and methods
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
WO2000019990A2 (en) * 1998-10-08 2000-04-13 Allergan Sales, Inc. Rar antagonists as male anti-fertility agents
US6093838A (en) * 1999-08-16 2000-07-25 Allergan Sales, Inc. Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US10829898B2 (en) 2018-04-13 2020-11-10 Gomaco Corporation Three-dimensional bridge deck finisher

Also Published As

Publication number Publication date
US20080214652A1 (en) 2008-09-04
EP1920771A3 (de) 2008-07-23
EP1920771A2 (de) 2008-05-14
WO2002089781A2 (en) 2002-11-14
EP1392284B1 (de) 2008-08-27
CA2445504A1 (en) 2002-11-14
EP1392284A2 (de) 2004-03-03
DE60228567D1 (de) 2008-10-09
US20020193403A1 (en) 2002-12-19
US20050171151A1 (en) 2005-08-04
WO2002089781A3 (en) 2003-03-27
JP2004532239A (ja) 2004-10-21

Similar Documents

Publication Publication Date Title
DE60228567D1 (de) Behandlung von hyperlipidämie
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
DE60138129D1 (de) Apparat zur behandlung von zähnen
DE60114808D1 (de) Oberflächenbehandlung von medizinischer vorrichtung
NO20034056D0 (no) Proliferative sykdommer
FI20011421L (fi) Menetelmä ja laite toiminnon toteuttamiseksi
DE60101642D1 (de) Vorrichtung zum Unterdrücken von elektrischem Rauschen und Rauschunterdrückungselement
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
NO20040635L (no) Forbedret shuntinnretning og fremgangsmate for behandling av glaukom
DE50214540D1 (de) Stanz bei der behandlung von wunden
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60132089D1 (de) Vorrichtung zur behandlung von gasen miitels plasma
DE60204286D1 (de) Implantierbare vorrichtung
NO20001870L (no) Ny fremgangsmÕte for behandling
ATE451921T1 (de) Phenylindole zur behandlung von hiv
ATE311200T1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
FI20011193L (fi) Menetelmä päätelaitteen akustisten ominaisuuksien parantamiseksi ja päätelaite
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE366569T1 (de) Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids
DE60224650D1 (de) Vorrichtung zur behandlung von vorhof-fibrillation
DE60033020D1 (de) Gerät zur behandlung von zahnkaries
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties